Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
11/12/2025
Dalet, a leading provider of cloud-native, end-to-end media workflow solutions, ...
20/11/2025
LONDON The winners of the Rise Awards 2025, which recognize women and companies whose achievements have stood out in the media technology industry, have been an...
20/11/2025
SANTA MONICA & NEW YORK Lionsgate's Worldwide Television Distribution Group and Debmar-Mercury have launched MovieSphere Gold in more than 30 million homes....
20/11/2025
ALAMEDA, Calif. Clear-Com has introduced its four-channel HelixNet beltpack, a next-generation advancement of its widely used two-channel model, and anticipates...
20/11/2025
NEW PROVIDENCE, N.J. Streaming technology and services provider Kiswe has launched Kiswe Core, a next-generation cloud-based platform designed to simplify the s...
20/11/2025
MOUNTAIN VIEW, Calif. Dolby Laboratories has signed on as an official signature partner of the Bay Area Host Committee (BAHC) for the 2026 Super Bowl and the we...
20/11/2025
STUTTGART, Germany 3 Screen Solutions (3SS) has announced that the Canadian multiservice operator Telus has launched its Telus TV+ entertainment platform on Sam...
20/11/2025
Major League Baseball has announced deals with ESPN, NBCUniversal and Netflix covering 2026-2028 that make ESPN the exclusive rightsholder of MLB.TV, see regula...
20/11/2025
Berklee Presents Holiday Extravaganza: Duke Ellingtons The Nutcracker Suite and ...
19/11/2025
Sphere Sound Kicks Up Its Heels at Radio City Music HallUltra-immersive system from the singular Las Vegas venue is also ready for sportsBy Dan Daley, Audio Edi...
19/11/2025
The Future of Stadium and Arena Video Control Rooms: Tech Leaders Talk 4K, IP, a...
19/11/2025
One Year at Intuit Dome: Walking Through the Stunning Arena's Advanced Video...
19/11/2025
SVG Sit-Down: IMG's Francois Westcombe Goes Inside IMG's Annual Digital ...
19/11/2025
Inside Brighton & Hove Albion's fan-first media machine By George Bevir
Tuesday, November 18, 2025 - 10:10
Print This Story
Brighton & Hove Albion'...
19/11/2025
Rock Chalk Rebuild, Part 1: Kansas Athletics Brings New Production Power to Rebu...
19/11/2025
Rock Chalk Rebuild, Part 2: A Pro's Guide to Kansas Athletics' New Video...
19/11/2025
MLB Media Rights Shakeup: NBC Inks Three-Year Deal for Sunday Night Baseball, Pe...
19/11/2025
Rohan Parashuram Kanawade attends the premiere of Sabar Bonda (Cactus Pears) at the 2025 Sundance Film Festival at Egyptian Theatre on January 26, 2025, in Pa...
19/11/2025
Awards season is heating up, and the International Documentary Association just ...
19/11/2025
Aerojet Rocketdyne President Ken Bedingfield and Arkansas Gov. Sarah Huckabee Sanders were joined by state and local officials to celebrate the groundbreaking o...
19/11/2025
L3Harris and PentenAmio formalise their teaming agreement at MilCIS 2025, streng...
19/11/2025
Calrec gives Phoenix Broadcast Solutions its full support in strategic multi-year enterprise partnership New Singapore OB company invests in Calrec technology f...
19/11/2025
October brings a larger audience in front of TV screens. The cooler autumn weather and the continuation of new programming schedules brought increases in both t...
19/11/2025
IRVING, Texas Nexstar Media Group and Tegna filed applications on Nov. 18 with the Federal Communications Commission (FCC) seeking its consent to transfer broad...
19/11/2025
Vitec has acquired Datapath, a developer of real-time video processing for large-scale video walls, AVoIP content distribution and KVM control in mission-critic...
19/11/2025
NEVADA CITY, Calif. Telestream has introduced ARGUS Version 2.3, which introduces Live Look, a feature that lets operators inspect live and on-demand streams vi...
19/11/2025
STAMFORD, Conn. and NEW YORK Charter Communications, Inc. has announced a major deal with Amazon Web Services (AWS) that establishes AWS as one of Charters stra...
19/11/2025
TOKYO Atomos has announced a major firmware update that brings integrated camera control to the Ninja TX GO and Ninja TX its new CFexpress-based monitor-recor...
19/11/2025
Berklee's Signature Series Reimagines the Musical and Visual Artistry of Col...
19/11/2025
PlayBox Neo departed the NAB Show New York 2025 on a high note. The company's all-new PlayBox Neo Suite made a splash on the show floor, drawing strong inte...
19/11/2025
AAVBR (American Audio Visual Baton Rouge), a leading full-service event production company serving Louisiana and the Gulf Coast region, has enhanced its product...
19/11/2025
In its mission to deliver live event services combining advanced engineering with a creative approach to captivating live sports and entertainment experiences, ...
19/11/2025
NEW YORK Short-form vertical video has exploded across platforms like TikTok, Instagram and YouTube, but a new survey commissioned by Media.net, a provider of c...
19/11/2025
NEW YORK YES Network, the regional sports network home of the New York Yankees and Brooklyn Nets, and CAMB.AI have struck a partnership they said will leverage ...
19/11/2025
WASHINGTON The Federal Communications Commission has issued detailed guidance on filings that were disrupted by the government shutdown. While many of those fil...
19/11/2025
NEW YORK The popularity of NFL games is largely responsible for continued seasonal momentum in TV viewership into October (measured Sept. 29-Oct. 26), according...
19/11/2025
DirecTV has announced that its MyFree DirecTV streaming service has added seven new channels. Those include four sports services, NBA FAST, Red Bull TV, DAZN Ri...
19/11/2025
SURREY, U.K. Mark Roberts Motion Control (MRMC) has launched Flair Bridge, a compact device that transforms how operators control the company's motion-contr...
19/11/2025
WASHINGTON The Federal Communications Commission, which is continuing to rapidly ramp up its operations after the end of the federal government shutdown, has se...
19/11/2025
IRVING, Texas Nexstar Media Group and Tegna filed applications on Nov. 18 with the Federal Communications Commission (FCC) seeking its consent to transfer broad...
19/11/2025
Martin Freeman, Jessie Buckley, Wu-Tang Clan's Raekwon, Eddie the Eagle and ...
19/11/2025
Rohde & Schwarz collaborates with Broadcom to enable testing and validation of n...
19/11/2025
Back to All News
Innato, starring Imanol Arias and Elena Anaya, arrives on Netf...
19/11/2025
Back to All News
Guillermo del Toro Sits Down With Troll 2 Director Roar Uthaug...
19/11/2025
Some projects feel monumental from the moment the first phone call comes in. When BCE, the host broadcaster appointed to coordinate the national coverage, asked...
19/11/2025
November 19 2025, 08:00 (PST) BAY AREA HOST COMMITTEE AND DOLBY PARTNER TO DELIVER IMMERSIVE FAN EXPERIENCES
During the Week of Football's Biggest Game...
19/11/2025
Michael D. Higgins: Ireland's Ninth President features RT Archives footage and interviews across seven decades
Watch Wednesday 19 November at 9:35pm on RT...
19/11/2025
Scripps Research scientists receive $1.1 million to advance AI modeling for HIV vaccine development New AI system helps scientists rapidly pinpoint the most pro...
18/11/2025
Independent media across Central America are operating under intensifying financial pressure, yet there is a clear appetite for models that can sustain both ind...
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
